Multiple-dose studies with glyburide in patients with type 2 diabetes demonstrate
drug level concentration-time curves similar to single-dose studies, indicating
no buildup of drug in tissue depots.
In the presence of normal renal function, there are no differences between
single- or multiple-dose pharmacokinetics of metformin between patients with
type 2 diabetes and normal subjects, nor is there any accumulation
of metformin in either group at usual clinical doses.
Hepatic Insufficiency
No pharmacokinetic studies have been conducted in patients with hepatic insufficiency
for either
glyburide or metformin.
Renal Insufficiency
No information is available on the pharmacokinetics of glyburide in patients
with renal insufficiency. In patients with decreased renal function (based
on creatinine clearance), the plasma and blood half-life of metformin is prolonged
and the renal clearance is decreased in proportion to the decrease in creatinine clearance.
Geriatrics
There is no information on the pharmacokinetics of glyburide in elderly patients. Limited
data from controlled pharmacokinetic studies of metformin in healthy elderly
subjects suggest that total plasma clearance is decreased, the half-life is
prolonged, and Cmax is increased, compared to healthy young subjects. From
these data, it appears that the change in metformin pharmacokinetics with
aging is primarily accounted for by a change in renal function. Metformin treatment should
not be initiated in patients =80 years of age unless measurement of creatinine
clearance demonstrates that renal function is not reduced.
Glucovance
Pregnancy
Metabolism and elimination
Patients with type 2 diabetes
Hypoglycemia
Mechanism of action
Metformin hydrochloride
Information for patients
Drug interactions
Overdosage
Glipizide (glucotrol)
Drugs without prescription
Online pharmacy - Med RX Pharmacy.